The narrative surrounding the BRCA1 and BRCA2 genetic mutations has, for decades, been framed almost exclusively as...
Sagoh
In a transformative period that has sent shockwaves through the biopharmaceutical sector, Dublin-based Alkermes has emerged as...
Nottingham, UK – In a monumental leap forward for oncology, scientists and clinicians in Nottingham have unveiled...
In 2020, the biotechnology sector witnessed a seismic shift when Bristol Myers Squibb (BMS) executed a $13...
For many individuals, the journey of cancer treatment is marked by profound physical transformations. Among the most...
Imagine managing a multi-billion-dollar clinical research project involving nearly six million individual data points. You have at...
By Yoga Journal Editorial Staff | June 22, 2026 In the vast lexicon of yoga asanas, few...
The Silent Crisis: Why the Biopharma Industry is Losing Its Most Valuable Asset During Tech Transfer
The Silent Crisis: Why the Biopharma Industry is Losing Its Most Valuable Asset During Tech Transfer
In the high-stakes world of biopharmaceutical manufacturing, the term "technology transfer" often conjures images of seamless data...
A groundbreaking Phase III clinical trial, the global OASIS study, has met its primary endpoint, demonstrating the...
New York, NY – March 14, 2024 – In a significant advance for cancer research, a preclinical...
